US Pharma Turns to China for Drug Innovation Amid Rising Competition
Key Points U.S. pharmaceutical companies are licensing drugs from China more frequently. In 2024, nearly 30% of major pharmaceutical deals involved Chinese companies. Chinese firms offer innovative drugs at lower costs and faster development timelines. Some fear this shift threatens...